ILCA | Association Partnerships

September 08, 2021

In an interview, Amaia Lujambio, MD discussed the diversity of genomic alterations in hepatocellular and advanced in molecular testing that could shape future understanding of the disease.

September 07, 2021

A study has shown that high interferon signaling and expression of MHC-II related genes can predict response to therapy is patients with advanced heptocellular carcinoma being treated for the first time.

September 06, 2021

Atezolizumab given in combination with bevacizumab led to an improvement in overall survival compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma.

September 05, 2021

Patients with inoperable intrahepatic cholangiocarcinoma have demonstrated tendency to live longer when elective internal radiation therapy with Y90 is added to chemotherapy.

September 05, 2021

Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.

September 04, 2021

Amaia Lujambio Goizueta, PhD, discusses mutations commonly seen in hepatocellular carcinoma, and the targeted therapies available for these tumors.